Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)

Autores: Richardson, P. G.; Oriol, A. ; Larocca, A. ; Rodríguez Otero, Paula; Moreb, J. ; Blade, J. ; Hassoun, H.; Cavo, M. ; Alegre, A.; Mazumder, A. ; Maisel, C.; Paner, A. ; Leleu, X. ; Zonder, J. A.; Harmenberg, J.; Thuresson, S.; Zubair, H. ; Mateos, M. V.